Study for people with Heart Disease

Recruiting Not a phased study

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Not a phased study
Sponsor Edwards Lifesciences
Registry number NCT05172960
Started 20 June 2022 Today 16 October 2026 Estimated completion 1 July 2027

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
St. Andrews War Memorial Hospital Spring Hill QLD Active not recruiting
Royal Adelaide Hospital Adelaide SA Active not recruiting
The Royal Melbourne Hospital Parkville VIC Active not recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age child, adult, older adult
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 1234

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

1. Severe, calcific AS

2. Native aortic annulus size suitable for SAPIEN X4 THV

3. NYHA functional class ≥ II

4. The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.

Exclusion Criteria:

1. Anatomical characteristics that would preclude safe femoral placement of the introducer sheath or safe passage of the delivery system

2. Aortic valve is unicuspid, bicuspid or non-calcified

3. Pre-existing mechanical or bioprosthetic valve in any position

4. Severe aortic regurgitation (\> 3+)

5. Severe mitral regurgitation (\> 3+) or ≥ moderate mitral stenosis

6. Need for mitral, tricuspid or pulmonic valve intervention within the next 12 months

7. Left ventricular ejection fraction \< 20%

8. Cardiac imaging evidence of intracardiac mass, thrombus or vegetation

9. Left ventricular outflow tract calcification that would increase the risk of annular rupture or significant PVL after THV implantation

10. Increased risk of coronary artery obstruction after THV implantation

11. Myocardial infarction within 30 days prior to the study procedure

12. Hypertrophic cardiomyopathy with subvalvular obstruction

13. Subjects with planned concomitant ablation for atrial fibrillation

14. Complex coronary artery disease (CAD) that cannot be optimally treated by percutaneous coronary intervention (PCI)

15. Any surgical or transcatheter procedure within 30 days prior to the study procedure (unless part of planned strategy for treatment of CAD). Implantation of a permanent pacemaker or implantable cardioverter defibrillator (ICD) is not considered an exclusion.

16. Any planned surgical or transcatheter intervention to be performed within 30 days following the study procedure (unless part of planned strategy for treatment of CAD)

17. Endocarditis within 180 days prior to the study procedure

18. Stroke, transient ischemic attack or neurological signs and symptoms attributed to carotid or vertebrobasilar disease within 90 days prior to the study procedure

19. Hemodynamic or respiratory instability requiring inotropic or mechanical support within 30 days prior to the study procedure

20. Renal insufficiency and/or renal replacement therapy

21. Leukopenia, anemia, thrombocytopenia

22. Inability to tolerate or condition precluding treatment with antithrombotic therapy

23. Hypercoagulable state or other condition that increases risk of thrombosis

24. Absolute contraindications or allergy to iodinated contrast that cannot be adequately treated with premedication

25. Subject refuses blood products

26. BMI \> 50 kg/m2

27. Estimated life expectancy \< 24 months

28. Female who is pregnant or lactating

29. Active SARS-CoV-2 infection or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments

30. Participating in another investigational drug or device study that has not reached its primary endpoint

31. Subject considered to be part of a vulnerable population

Dates on the record

Started 20 June 2022
Estimated completion 1 July 2027
Registry last updated 24 September 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 24 September 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.